Benjamin F. Edwards & Company Inc. grew its position in shares of Eli Lilly and Co (NYSE:LLY) by 13.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,321 shares of the company’s stock after acquiring an additional 976 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Eli Lilly and were worth $703,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Pathstone Family Office LLC boosted its holdings in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. acquired a new position in shares of Eli Lilly and during the second quarter valued at $494,000. Acrospire Investment Management LLC boosted its holdings in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Eli Lilly and during the second quarter valued at $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new position in shares of Eli Lilly and during the second quarter valued at $129,000. 76.35% of the stock is owned by institutional investors.

Shares of Eli Lilly and Co (LLY) opened at $85.49 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Co has a 1 year low of $74.00 and a 1 year high of $89.09. The company has a market cap of $94,130.00, a PE ratio of 40.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the business earned $0.88 earnings per share. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly and Co will post 4.22 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.63%. Eli Lilly and’s payout ratio is 99.05%.

In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 251,088 shares of company stock worth $22,041,236. 0.20% of the stock is owned by company insiders.

Several equities analysts have recently issued reports on the stock. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the company a “buy” rating in a report on Tuesday. Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $86.98 to $95.00 in a research note on Tuesday. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Finally, BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 12th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $92.75.

TRADEMARK VIOLATION NOTICE: “Benjamin F. Edwards & Company Inc. Has $703,000 Stake in Eli Lilly and Co (LLY)” was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/benjamin-f-edwards-company-inc-has-703000-stake-in-eli-lilly-and-co-lly/1814927.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.